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Some biologics can modulate cytokines that may lead to changes in expression of drug-
metabolizing enzymes and cause drug-drug interactions (DDI). DDI potential of TV-
1106—an albumin-fused growth hormone (GH)—was investigated. In this study, human
blood was exposed to recombinant human growth hormone (rhGH) or TV-1106, fol-
lowed by isolation of the plasma and its application to human hepatocytes. While the
treatment of blood with rhGH increased multiple cytokines, treatment of blood with
TV-1106 had no effect on any of the nine cytokines tested. The interleukin (IL)-6 con-
centration was higher in the rhGH then in the TV-1106-treated plasma (P < .05). While
rhGH had little or no effect on CYP1A2 or CYP2C19 mRNA but increased CYP3A4
mRNA twofold, TV-1106 had little or no effect on cytochrome P450 (CYP) mRNAs in
hepatocytes. Although the plasma from rhGH-treated blood lowered CYP1A2 activity,
the TV-1106 plasma had no effect on CYP activities. The CYP1A2 activity was lower in
the rhGH- then in the TV-1106-plasma treated hepatocytes (P < .05). The results indi-
cated that fusing GH with albumin made TV-1106 an unlikely participant of CYP1A2,
CYP2C19 or CYP3A4-facilitated, direct or cytokine-driven DDI.
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1 | INTRODUCTION
The ability to predict drug interactions concerning biotherapeutics
that can modify cytokines and potentially impact cytochrome P450
(CYP) enzymes, has been of growing interest to pharmaceutical com-
panies and regulatory agencies. The 2012 Food and Drug Adminis-
tration (FDA) guidance on drug interactions recommended
assessment of therapeutic proteins that are cytokines or cytokine
modulators (that have recognized effects on CYPs), are to be used
concurrently with small molecule drugs, or cases where mechanisms
other than biologics’ influence on CYPs or transporters were identi-
fied.1 The mechanism of therapeutic protein drug-drug interaction
(DDI) implicates cytokine-mediated suppression of xenobiotic metab-
olizing enzymes. Multiple human investigations have documented
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the effect of cytokines and their modulators on CYPs and trans-
porters.2
TV-1106 is recombinant human growth hormone (rhGH) genetically
fused to recombinant human albumin (rhA). Fusion of rhGH and rhA—a
carrier protein without hormone activity, but with a long plasma half-life
—is expected to extend systemic circulation of rhGH and preserve its
activity.3,4 TV-1106 is being developed for the treatment of GH defi-
ciency to provide a sustained exposure that can reduce the frequency
of injections and consequently improve compliance and quality of life
for patients.3 Phase 1 clinical trial demonstrated that the TV-1106 is
well tolerated, has a prolonged plasma half-life, and is hormonally active
in GH-deficient adult patients.5 Side effects of GH therapy are rare and
rhGH was shown to have a favorable overall safety profile.6 But it is
noted that children with Turner syndrome who were treated with rhGH
exhibited a higher risk for targeted adverse effects (intracranial hyper-
tension, slipped capital femoral epiphysis, scoliosis, and pancreatitis).7
GH also increased synthesis of inflammatory cytokines interlukin-1-a
(IL-1-a), IL-6 and tumor necrosis factor-a (TNF-a) by lipopolysaccharide
(LPS)-activated monocytes in whole blood; and its administration at high
doses to critically ill adults was associated with an increase in morbidity
and mortality.8
Morgan et al9 demonstrated that GH was a central regulator of
CYP expression in rat livers. A separate investigation revealed induc-
tion of CYP3A4 in cultured human hepatocytes after exposure to
GH.10 Studies in GH-deficient children and adults have shown that
the peptide affects the half-life of CYP-metabolized drugs.11–14 The
GH induced CYP1A2 and inhibited CYP2C19, while the hormone did
not change CYP2D6 and CYP3A4 enzymes in healthy elderly men.15
An evaluation of TV-1106 effects on plasma cytokines and on bio-
transformation of small molecules in the liver is warranted since
rhGH also modulated plasma cytokines in GH-deficient and normal
children of short stature.16,17 We developed a method for evaluation
of biologics as direct and cytokine-mediated determinants of hepatic
biotransformation of xenobiotics. The assay is based on a treatment
of whole blood with the biologic drug, followed by application of the
resulted stimulated plasma to cultured hepatocytes.18 The CYPs
selected for this study dominate xenobiotic metabolism in human
liver and are suppressed by IL-6 in vitro. We examined the ability of
TV-1106 or rhGH to initiate cytokine release in whole blood and the
effect of the drugs themselves or the stimulated plasma on CYPs
1A2, 2C19, and 3A4 expression in human hepatocytes.
2 | MATERIALS AND METHODS
2.1 | Chemicals and reagents
TV-1106, rhGH and a sterile drug vehicle were (10 mM sodium phos-
phate, 200 mM mannitol, 60 mM trehalose dehydrate, 0.08% (w/v)
polysorbate 80, pH 7.2) provided by Teva Pharmaceutical Industries
Ltd. Escherichia coli LPS was purchased from Sigma-Aldrich (St. Louis,
MO). Blood was donated by healthy volunteers who gave informed con-
sent to participate in the study. IL-6 and TRIzol were purchased from
EMD Biosciences (La Jolla, CA) and Invitrogen (Grand Island, NY),
respectively. The sources of the other reagents used in this study have
been described elsewhere.19
2.2 | Cytokine release assay
Blood from four donors (three male, one female, 25-53 years old) was
drawn into multiple sterile glass 10 mL vacutainers containing sodium
heparin (Becton-Dickinson, Franklin Lakes, NJ), transferred into sterile
50 mL polypropylene tubes (BD Biosciences, San Diego, CA) and ali-
quoted into sterile polypropylene micro tubes (Sarstedt, Newton, NC).
The concentration of rhGH applied to whole blood was about 15 times
higher than Cmax (~80 lg/L) measured in GH-deficient children dosed
with 0.75 or 1.5 mg/kg of Nutropin Depot (somatropin).20 The drug vehi-
cle (1% v/v), LPS (50 lg/mL), rhGH (1.25 lg/mL), or TV-1106 (5 lg/mL,
concentration equimolar to rhGH) were added to blood, gently mixed
and incubated at 37°C for 24 hours. Plasma was separated from whole
blood by centrifugation at 600g for 10 minutes, aliquoted and stored at
80°C. Interferon (IFN)-c, interleukin-1b (IL-1b), IL-2, IL-6, IL-8, IL-10, IL-
12p70, TNF-a and granulocytes monocyte-colony stimulating factor
(GM-CSF) were measured in the plasma by sandwich immunoassay with
electrochemiluminescence detection (Human Proinflammatory 9-Plex
Ultra-Sensitive Kit, Meso Scale Discovery, Gaithersburg, MD) according
to the manufacturer’s instructions. The measurements were conducted
by Viracor-IBT Laboratories (Lee’s Summit, MO) with Meso Scale
Discovery Sector Imager 2400. The lower and upper limits of cytokine
quantitation were 0.6 and 2500 pg/mL, respectively.
2.3 | Hepatocyte culture and treatments
Hepatocytes were isolated from six nontransplantable livers by a two-
step collagenase perfusion method and plated on collagen-coated 24-
well plates, as described previously.21 This isolation procedure routinely
resulted in a coculture of hepatocytes and liver macrophages and the
cells were treated according to published protocols.19,22 Briefly, the
confluent cocultures were achieved with ~4 9 105 cells per well, over-
laid with Matrigel 2-3 hours after seeding and were adapted to culture
conditions for 2-3 days with daily changes of medium. Following the
adaptation period, the cells were treated once daily for 3 consecutive
days with modified Chee’s medium (MCM+), containing 0.1% v/v
dimethyl sulfoxide (DMSO) (vehicle, negative control), IL-6 (10 ng/mL,
positive control), 0.5% v/v drug vehicle, TV1106 (2.5 lg/mL) or 1 of 2
known human CYP enzyme inducers, namely, omeprazole (100 lmol/L)
and rifampin (10 lmol/L). The MCM+ was supplemented with
0.98 lmol/L dexamethasone. In addition, the hepatocytes were treated
with plasma from drug vehicle-, LPS-, rhGH-, or TV-1106-treated blood.
Aliquots of pooled plasma were thawed on the day of treatment. The
plasmas were added to cultured cells at 10%, 20%, or 50%, v/v. Follow-
ing last treatment, the cell culture medium was removed and the cells
were washed with 1X phosphate buffered saline. Fresh incubation med-
ium without plasma was added containing phenacetin (100 lmol/L), S-
mephenytoin (400 lmol/L) or midazolam (30 lmol/L). After 30-minutes
incubation with these probe substrates, 150 lL of the medium was
mixed with an equal volume of acetonitrile containing an appropriate
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internal standard, as described in Paris et al.19 Metabolite formation
was analyzed by liquid chromatography-tandem mass spectrometry
(LC-MS/MS) for the formation of acetaminophen (CYP1A2),
40-hydroxymephenytoin (CYP2C19) or 10-hydroxymidazolam (CYP3A).
Details of the analytical methods are given in Table S1. Additional cells
were lysed with TRIzol for isolation of mRNA.
2.4 | Cytotoxicity assessment
The leakage of lactate dehydrogenase in hepatocyte cultures was
determined by the method provided by Roche Diagnostics (Catalog
# 116447930010). Daily light microscopic examinations of the cul-
tures throughout the culturing period were conducted.
2.5 | mRNA analysis
Total RNA was phase extracted with TRIzol followed by purification
with an RNeasy Mini Kit (Qiagen, Valencia, CA). Purified RNA was
reverse transcribed to cDNA with the High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, Carlsbad, CA) and the Applied
Biosystems 7300 real-time PCR System (AB7300). Quantitative PCR
was performed with the AB7300 with the Applied Biosystems
Universal Master Mix and TaqMan Gene Expression Assays. CYP
mRNA levels were normalized to the levels of glyceraldehyde 3-
phosphate dehydrogenase mRNA, which were assumed to remain
unaffected by the in vitro treatments.
2.6 | Data processing and statistical analysis
All data were processed and graphed with Microsoft Excel software
(Office 2007; Microsoft, Redmond, WA). One-way analysis of the
effects of rhGH and TV-1106 on the cytokine release in the whole
blood was conducted with the nonparametric Wilcoxon test (Rank
Sums). This type of statistical analysis was selected following the
recognition of the large variability in the data, meaning the normality
of the data cannot be assumed. Two-way analysis of variance on
the effects of drug vehicle, TV-1106 or rhGH plasma on CYPs
mRNA and enzyme activity was conducted using the Wilcoxon test,
for similar reasons as stated earlier. All statistical analysis was done
with a software package—JMP Statistical Discovery Ver. 12.0.1, SAS
Institute Inc., Cary, NC.
3 | RESULTS
3.1 | Effects of rhGH and TV-1106 on cytokine
release in human whole blood in vitro
The effects of drug vehicle, LPS, rhGH or TV-1106 on the release of
IFN-c, IL-1b, IL-2, IL-6, IL-8, IL-10, IL-12p70, TNF-a, and GM-CSF in
whole blood are presented in Table 1. Statistical analysis of the data
is shown in Table S2. Treatment of whole blood with LPS, a positive
control, caused the expected release of cytokines. Treatment of
whole blood with rhGH increased all but IL-12p70 cytokine,
between 2.29- and 27.8-fold above the vehicle control. However,
the increases of the cytokines were not statistically significant.
Treatment of whole blood with TV-1106 changed cytokines concen-
tration between 0.51- and 4.3-fold of vehicle control. The nonpara-
metric Wilcoxon test (Rank Sums) did not reveal significant
differences in the cytokine concentrations between the TV-1106
and vehicle control (analysis not shown). Statistical tests revealed a
significant drop of IL-6 in the TV-1106 group as compared to the
rhGH group (P < .05).
3.2 | Cytotoxicity assessment
Lactate dehydrogenase released into the cell culture medium at 24,
48, and 72 hours was lower in the cultures treated with TV-1106
than rhGH for all 3 hepatocyte donors (data not shown). Daily light
microscopic examinations of the cells throughout the culturing per-
iod did not reveal signs of toxicity.
TABLE 1 The effects of drug vehicle, LPS, rhGH, or TV-1106 on cytokine release in whole human blood ex vivo
Vehicle (1% v/v) LPS (50 lg/mL) rhGH (1.25 lg/mL) TV-1106 (5 lg/mL)
Interferon-c 15.3  15.1a, b 2990  4180 (196) 39.6  55.5c (2.59) 7.73  13.6 (0.506)
Interleukin-1ß 4.64  2.92 13 200  364 (2850) 90.1  67.8 (19.4) 20.1  17.8 (4.32)
Interleukin-2 32.9  41.1 317  315 (9.64) 213  175 (6.47) 61.3  53.9 (1.87)
Interleukin-6 31.7  42.2 15 100  3190 (476) 879  856* (27.8) 78.4  99.1 (2.48)
Interleukin-8 2540  1960 10 900  310 (4.29) 5810  3150 (2.29) 3510  2640 (1.38)
Interleukin-10 8.81  4.65 1200  652 (136) 27.5  22.7 (3.13) 5.12  4.50 (0.581)
Interleukin-12p70 23.7  20.3b 46.0  43.8 (1.94) 5.25  4.64b (0.222) 12.7  7.49c (0.536)
Tumor necrosis factor-a 19.5  15.9 8500  4200 (435) 134  144 (6.88) 26.8  15.2 (1.37)
Granulocyte monocyte-CSF 81.7  50.2 470  330 (5.75) 306  320 (3.75) 225  215 (2.75)
LPS, lipopolysaccharide; rhGH, recombinant human growth hormone; CSF, colony-stimulating factor; BLQ, below level of quantitation.
aValues are mean  standard deviation in pg/mL (fold change from vehicle) of duplicate determinations in blood from four donors.
bValues from two donors in this group were BLQ.
cValue from one donor in this group was BLQ.
*IL-6 concentration was statistically higher in rhGH than in the TV-1106 group, nonparametric Wilcoxon tests (Rank Sums) P < .05 (Table S2).
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3.3 | Effects of rhGH and TV-1106 on CYP and
IGF-1 mRNAs in human hepatocytes in vitro
To establish an in vitro equivalence of TV-1106 and rhGH, human
hepatocytes (donors H1270, H1271, and H1272) were treated with
vehicle, IL-6, rhGH or TV-1106. The TV-1106 was at equimolar con-
centrations to rhGH with regard to the hormone portion of the
fused molecule. The effects of the treatments on CYPs 1A2, 2C19,
3A4 and insulin-like growth factor-1 (IGF-1) mRNAs are shown in
Figure 1. Treatment of hepatocytes with IL-6 resulted in the
expected suppression of CYP mRNAs and a twofold increase in IGF-
1 mRNA. The CYPs and IGF-1 mRNA responses to equimolar
concentrations of rhGH and TV-1106 were not statistically different
in three cultures of hepatocytes (t test: paired two sample for
means, a = 0.05, Microsoft Excel 2010, data not shown). The effects
of treating additional cultures of hepatocytes with 0.1% DMSO,
omeprazole, phenobarbital or rifampin on the CYP mRNAs and
enzyme activities are presented in Table S3. As expected, treatment
of hepatocytes with omeprazole caused, on average, a 79.2-fold
increase in CYP1A2 mRNA levels. Treatment of hepatocytes with
rifampin caused, on average, a 3.3- and 63.1-fold increase in
CYP2C19 and CYP3A4 mRNA levels, respectively. Omeprazole,
rifampin and phenobarbital caused, on average, about 50% reduction
in IGF-1 mRNA levels.
F IGURE 1 Effects of incubating human hepatocytes with equimolar, with respect to the hormone portion of the molecule, concentrations
of rhGH and TV-1106 on CYPs 1A2, 2C19, 3A4, and IGF-1 mRNA. Primary human hepatocytes (donors H1270, H1271, and H1272) were
incubated for 72 hours with medium containing vehicle (0.5% v/v), IL-6 (10 ng/mL), rhGH (0.312, 0.625, or 1.25 lg/mL) or TV-1106 (1.25, 2.5,
or 5.0 lg/mL). The mRNA levels were measured by quantitative PCR and normalized first to the levels of GAPDH mRNA and then to the
levels of CYPs 1A2, 2C19, 3A4, and IGF-1 mRNA in hepatocytes incubated with cell culture medium containing drug vehicle. The mRNA
values are the mean and standard deviation of measurements in 3 cultures. Differences in the rhGH and TV-1106 levels of the mRNAs were
not significant (t test: paired two sample for means, a = 0.05, Microsoft Excel 2010). rhGH, recombinant human growth hormone; CYPs,
cytochrome P450; IGF-1, insulin-like growth factor-1; IL, interleukin; GAPDH, glyceraldehyde 3-phosphate dehydrogenase
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3.4 | Effects of TV-1106 on CYP mRNAs and
enzyme activities in human hepatocytes in vitro
The effects of treating cultured human hepatocytes (donors H1091,
H1097, and H1108) with vehicle, TV-1106, or IL-6 on CYP mRNAs
expression and enzyme activity are shown in Figure 2. The effects
of treating hepatocytes with 0.1% DMSO, omeprazole or rifampin
caused expected changes in CYP mRNA levels and corresponding
enzymatic activities (Table S3). The mRNA levels in these cultures
were comparable to those in the donors H1270, H1271, and H1272
(Table S3). Treatment of human hepatocytes with IL-6 caused, on
average, 53%, 38%, and 94% suppression and 82%, 53%, and 86%
F IGURE 2 Effects of incubating human hepatocytes with TV-1106 or plasma prepared from whole human blood treated with drug vehicle,
LPS, rhGH or TV1106 on CYPs 1A2, 2C19 and 3A4 mRNA and enzyme activity. Primary human hepatocyte cultures were incubated for
72 hours with medium containing vehicle (0.5% v/v), IL-6 (10 ng/mL), TV-1106 (2.5 lg/mL) or zero, 10%, 20%, or 50% plasma prepared from
whole human blood treated with drug vehicle (1% v/v), LPS (50 ng/mL), rhGH (1.25 lg/mL) or TV-1106 (2.5 lg/mL). Plasma was pooled from
four blood donors. The levels CYPs 1A2, 2C19, and 3A4 mRNA were measured by quantitative PCR and normalized first to the levels of
GAPDH mRNA and then to the levels of CYPs 1A2, 2C19, and 3A4 mRNA in hepatocytes incubated with cell culture medium containing drug
vehicle or plasma from blood treated with drug vehicle alone. The enzymatic activity of CYPs 1A2, 2C19, and 3A was determined in situ with
30-minute incubations with phenacetin, S-mephenytoin or midazolam, respectively, as described in Materials and Methods. Values are the
mean and standard deviation of measurements in three cultures of hepatocytes (Table S4). * - CYP1A2 mRNA in the rhGH plasma group (10%)
was significantly lower than TV-1106, p<.05. CYP1A2 enzyme activity in the rhGH plasma groups (10 – 50%) was significantly lower than TV-
1106, p<.005. CY3A4 mRNA and enzyme activity in the rhGH were significantly lower than TV-1106, p<.01 (Supplemental Table 2). LPS,
lipopolysaccharide; rhGH, recombinant human growth hormone; CYPs, cytochrome P450; IL-6, interlukin-6; GAPDH, glyceraldehyde
3-phosphate dehydrogenase
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reduction in CYPs 1A2, 2C19, and 3A4 mRNA and enzyme activity,
respectively. Treatment of human hepatocytes with TV-1106 caused
little or no change in CYP1A2 and CYP2C19 mRNA levels or enzyme
activity. Treatment of human hepatocyte with TV-1106 caused little
or no change in CYP3A4 mRNA levels (26% increase) or in CYP3A
activity (66% increase); however, in 1 donor, this treatment had 34%
of the rifampin effect at inducing CYP3A activity.
3.5 | Effects of plasma from drug vehicle-, LPS-,
rhGH, or TV-1106-treated blood on CYP mRNAs and
enzyme activities in human hepatocytes in vitro
Data from hepatocytes (donors H1091, H1097, and H1108) incu-
bated with 10%, 20% or 50% plasma from LPS-, rhGH-, or TV-1106-
treated blood were normalized to cultures from drug vehicle-treated
plasma cultures at corresponding plasma concentrations (Figure 2,
Table S4). Statistical analysis of the data is presented in Table S2. As
expected, treatment of human hepatocytes with plasma from LPS-
treated blood caused up to an 85% suppression of CYP1A2 mRNA
levels and a reduction of up to 87% of phenacetin O-dealkylation
activity. Treatment of hepatocytes with plasma from rhGH-treated
blood caused a concentration-dependent suppression of up to 54%
of CYP1A2 mRNA levels and a reduction of up to 42% in CYP1A2
activity. Treatment of hepatocytes with plasma from TV-1106-trea-
ted blood caused a concentration-dependent suppression of up to
41% of CYP1A2 mRNA levels, but had little or no effect on CYP1A2
activity (8% decrease to 13% increase in 3 cultures). The TV-1106 or
rhGH plasma, as compared to control, did not have a significant
effects on CYP1A2 mRNA. The rhGH plasma decreased CYP1A2
mRNA as compared with the TV-1106-plasma(P < .05), and it dose-
dependently reduced CYP1A2 enzyme activity, as compared to the
TV-1106-plasma (P < .005).
Treatment of human hepatocytes with 10% plasma from LPS-
treated blood had little effect on CYP2C19 mRNA expression (a
49% increase), while treatment with 20% or 50% of this plasma
decreased CYP2C19 mRNA levels up to 30%. Treatment of hepato-
cytes with plasma from LPS-treated blood caused up to a 78%
decrease in S-mephenytoin 40-hydroxylation. Treatment of hepato-
cytes with plasma from rhGH- or TV-1106-treated blood caused
decreases of up to 34% and 37% in CYP2C19 mRNA levels, respec-
tively, and reductions of 44% and 23% in CYP2C19 activity, respec-
tively. The TV-1106-plasma, as compared to the rhGH-plasma, did
not have a significant effect on CYP2C19 mRNA or enzyme activity.
Treatment of cultured human hepatocytes with plasma from
LPS-treated blood caused the suppression of CYP3A4 mRNA levels
in 2 hepatocyte cultures (donors H1091 and H1108), but caused an
unexpected increase in CYP3A4 mRNA levels in the third hepatocyte
culture (up to 6.43-fold, donor H1097). Treatment of hepatocytes
with 10%, 20%, or 50% plasma from LPS-treated blood caused, on
average, 85%, 77%, and 66% reduction in midazolam 10-hydroxylase,
respectively. Treatment of hepatocytes with up to 50% plasma from
rhGH-treated blood caused a decrease of up to 73% in CYP3A4
mRNA levels and a corresponding decrease of up to 45% in CYP3A
activity. Treatment of hepatocytes with up to 50% plasma from TV-
1106-treated blood caused little change in CYP3A4 mRNA levels (up
to a 77% increase) and a corresponding increase (up to 48%) in
CYP3A activity. The rhGH plasma, as compared to TV-1106 plasma,
significantly decreased CYP3A4 mRNA and enzyme activity
(P < .01).
4 | DISCUSSION
We compared the ability of TV-1106, an albumin-fused GH, and
rhGH to stimulate cytokine release in whole human blood and the
effects of the plurality of the released cytokines on hepatic drug
metabolism in vitro. We found that genetically fusing GH to albumin
attenuated the peptide cytokine response in whole blood and its
effects on CYPs 1A2, 2C19, and 3A4 mRNA and enzyme activity in
hepatocytes from healthy donors. The cytokine and CYP in vitro
response to TV-1106 demonstrated weak-to-no DDI potential of the
drug compared to rhGH. The essential findings of this investigation
are in agreement with earlier studies. Liddle et al10 observed an
increase in CYP3A4 mRNA in hepatocytes treated with rhGH or
dexamethasone while CYP1A2 mRNA was decreased on day 4 of
the culture but increased on day 6, as compared to the vehicle. Simi-
larly, we did not observe an effect of rhGH on CYP1A2 mRNA,
while the increase in CYP3A4 mRNA was, as expected, lower than
that reported by Liddle since we cultured the cells in MCM+ con-
taining dexamethasone. Effects of GH, dexamethasone, or both com-
pounds together on CYP mRNAs were studied in human
hepatocytes.23 Authors observed an inductive effect of dexametha-
sone on CYP1A2 mRNA and protein level. The GH treatment sup-
pressed CYP1A2 in male hepatocytes but had neither an inductive
nor suppressive effect on the CYP1A2 mRNA in cultures from
female donors. In agreement with our culture medium containing
dexamethasone, the authors stated that a combination of constant
GH and dexamethasone was more inductive for CYP3A4 mRNA than
GH alone.
Pagani et al17 reported significant increases of TNF-ɑ and IL-6,
but not in IL-4 or IL-12, in GH-deficient children during substitutive
GH therapy. Bozzola et al16 found that in normal short stature chil-
dren application of GH increased plasma concentration of IGF-1,
IFN-c, IL-1b, IL-2, IL-12, and TNF-ɑ. In our study GH increased IL-
1ß, IL-2, and IL-6 and it had little or no effect on IL-12p70 in blood
from healthy adults, but these changes were not statistically signifi-
cant. In our study, the TV-1106 cytokine response, as compared
with GH, was significantly lower only for IL-6, and it can be attribu-
ted to steric hindrance of the peptide interaction with its molecular
partners due to close proximity of the albumin.
Human hepatocytes cultured on Matrigel-coated culture dishes
have been shown to maintain GH-responsiveness, as demonstrated
by an increase in IGF-1 and CYP3A4 mRNAs and CYP3A enzyme
activity.10 We hypothesize that the lack of a direct effect of albu-
min-fused GH on CYPs in our system is due to steric hindrance of
the peptide by albumin.
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Indirect, cytokine-mediated, suppression of mRNA and reduction
in enzyme activity of CYP1A2 and CYP3A4 by plasma from blood
treated with LPS were expected.18,24 In our study the cytokine-
mediated effect of albumin-fused rhGH is attenuated, likely due to
reduced cytokine response to TV-1106 as compared to rhGH.
We recognize that this study has a limitation, one of which is
that only four blood donors we used in the cytokine release assay.
This experimental design is therefore the simplest form of repeated
measures, however, the correlation between pairs of the observa-
tions was not very consistent so analysis of repeated measures can
be neglected. This limitation has a bearing on assigning causality to
the observed limited responsiveness of hepatic CYPs in TV-1106- as
compared to the rhGH-treated cells. Despite the low number of the
observations in the cytokine release assay, Wilcoxon test supported
a finding that rhGH treatment of the blood, but not that with TV-
1106, resulted in increased level of IL-6. Other limitation of the
study is that potential cytokine release from macrophages at the site
of drug injection and lymphatic and blood vessel endothelial cells is
not accounted for in vitro.
Study of human GH noncovalently attached to albumin did not
identify safety concerns with the molecule, which was intended for
a once weekly dosing.25 Also, a recombinant fusion protein of albu-
min and IFN did not increase adverse respiratory events in patients
with chronic hepatitis C virus, as compared to pegylated IFN, which
indicated that modifying IFN with albumin was as safe as pegylation
of the cytokine.26
Taken together, our data and investigations of other albumin-
linked peptides identify albumin as a safe carrier protein for a deliv-
ery of sustained dose of GH. Since TV-1106 appeared to have
reduced ability to stimulate cytokine release and to exert cytokine-
mediated effects on hepatic CYPs 1A2, 2C19 and 3A4, we conclude
that DDIs mediated by these enzymes are unlikely.
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